Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report

Clinical Lung Cancer(2021)10.1016/j.cllc.2021.01.009Source: DataRank Database

Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report is a research paper published in Clinical Lung Cancer (2021). On theSindex it has a DataRank of 0. It has been cited 7 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)OA: greenTopics (34)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Isa Mambetsariev ORCID,Rebecca Pharaon ORCID,Jeremy Fricke ORCID,Angel Ray Baroz,Hannah Romo

Live enrichment

PubMed:33640299 PMC:PMC8978804

NCI NIH HHS

Grant: P30 CA033572

National Institutes of Health

Grant: R01CA218545

NCI NIH HHS

Grant: U54 CA209978

NCI NIH HHS

Grant: R01 CA247471

National Institutes of Health

Grant: 5P30CA033572-27

Developmental Funds

National Institutes of Health

Grant: 5U54CA209978-06

Combating Subclonal Evolution of Resistant Cancer Phenotypes

National Institutes of Health

Grant: 5R01CA247471-03

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

National Institutes of Health

Grant: 5R01CA218545-02

Novel approach to attenuate small cell lung cancer growth and metastasis

National Cancer Institute

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8978804

https://doi.org/10.1016/j.cllc.2021.01.009

https://pubmed.ncbi.nlm.nih.gov/33640299

https://dx.doi.org/10.1016/j.cllc.2021.01.009

Fields of Study

0301 basic medicine03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperazinesPhthalazinesBRCA2 ProteinTreatment OutcomeDrug Therapy, CombinationGerm-Line MutationAdultFemaleAntibodies, Monoclonal, HumanizedMaternal Inheritance

Keywords

ImmunotherapyNSCLCGermline mutationOlaparibPrecision MedicineAdultBRCA2 ProteinLung NeoplasmsAntibodies, Monoclonal, HumanizedPiperazinesTreatment OutcomeCarcinoma, Non-Small-Cell LungHumansPhthalazinesDrug Therapy, CombinationFemaleMaternal InheritanceGerm-Line Mutation

Sustainable Development Goals

SDG 3: 3. Good health

Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report

FAIR Checklist

Authors (9)

Funding (9 grants)

Open Access

Topics

Annotations (Europe PMC)